机构：[1]State Key laboratory of Quality Research in Chinese Medicine/Macau Institute for Applied Researchin Medicine and Health, Macau University of Science and Technology, Taipa, Macau SAR 999056[2]Respiratory Medicine Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000[3]Respiratory Medicine Department, The Second Chinese Medicine Hospital of Sichuan Province,Chengdu, Sichuan 610031[4]Department of Respiratory Medicine, The Third People's Hospital ofChengdu/Affiliated Hospital of Southwest Jiaotong University, Chengdu, Sichuan 610000, P.R. China
Lung cancer is one of the most prevalent types of cancer worldwide, with a poor prognosis for patients and a concomitant financial burden on society. There are a number of different pathological subtypes, with non-small cell lung cancer (NSCLC) being the primary subtype. Although anticancer therapy has led to a marked improvement in the survival rate of patients in recent years, the survival rate remains poor. Potential reasons for this include a lack of early diagnosis and drug resistance, which is considered to be associated with mutations in components of signaling pathways, tumor suppressors and epidermal growth factor receptor, and certain other complex mechanisms to a certain extent. It is therefore imperative to develop novel therapies. In the present study, the pyrazolopyrimidine compound PP2 was used to inhibit Src family protein tyrosine kinases in A549 cells. It was demonstrated that PP2 was able to suppress cell viability, migration and invasion, and promote apoptosis via regulating the phosphoinositide 3-kinase/protein kinase B/B-cell lymphoma 2/caspase-3 signaling pathway. PP2 may therefore be useful in anti-NSCLC therapy in the future.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类|4 区医学
小类|4 区肿瘤学
最新[2023]版：
大类|4 区医学
小类|4 区肿瘤学
第一作者：
第一作者机构：[1]State Key laboratory of Quality Research in Chinese Medicine/Macau Institute for Applied Researchin Medicine and Health, Macau University of Science and Technology, Taipa, Macau SAR 999056[2]Respiratory Medicine Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000
共同第一作者：
通讯作者：
通讯机构：[2]Respiratory Medicine Department, Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan 646000[4]Department of Respiratory Medicine, The Third People's Hospital ofChengdu/Affiliated Hospital of Southwest Jiaotong University, Chengdu, Sichuan 610000, P.R. China[*1]Department of Respiratory Medicine, The Third People's Hospital of Chengdu/Affiliated Hospital of Southwest Jiaotong University, 82 Qinglong Street, Chengdu, Sichuan 610000, P.R. China[*2]Respiratory Medicine Department, Affiliated Hospital of Southwest Medical University, 25 Taiping Street, Luzhou, Sichuan 646000, P.R. China
推荐引用方式(GB/T 7714)：
Dai Xi,Wang Li-Jiao,Wu Juan,et al.Src kinase inhibitor PP2 regulates the biological characteristics of A549 cells via the PI3K/Akt signaling pathway.[J].Oncology letters.2018,16(4):5059-5065.doi:10.3892/ol.2018.9282.
APA：
Dai Xi,Wang Li-Jiao,Wu Juan,Shi Ya-Xu,Li Guo-Ping&Yang Xiao-Qiong.(2018).Src kinase inhibitor PP2 regulates the biological characteristics of A549 cells via the PI3K/Akt signaling pathway..Oncology letters,16,(4)
MLA：
Dai Xi,et al."Src kinase inhibitor PP2 regulates the biological characteristics of A549 cells via the PI3K/Akt signaling pathway.".Oncology letters 16..4(2018):5059-5065
